Atara Biotherapeutics, Inc. reported a net income of $32.7 million for the year ended December 31, 2025, a significant shift from the $85.4 million net loss in 2024. This turnaround was primarily attributed to commercialization revenue combined with substantial reductions in operating expenses. As of December 31, 2025, the company's cash and cash equivalents totaled $8.5 million, a decrease from $42.5 million in the previous year. The company's revenue for 2025 was $120.8 million, slightly lower than the $128.9 million reported in 2024, with the decrease primarily due to a year-over-year reduction in revenue from transition activities after tab-cel manufacturing and clinical activities transitioned to Pierre Fabre.
The company's research and development expenses significantly decreased to $37.4 million in 2025 from $151.5 million in 2024, reflecting the impact of workforce reductions and the transfer of tab-cel manufacturing and development responsibilities to Pierre Fabre. General and administrative expenses also decreased to $26.3 million in 2025 from $39.9 million in 2024, primarily due to reduced headcount. The company's strategic decision to pause development of its allogeneic CAR T cell programs and discontinue related operations, including terminating clinical trials for ATA3219 and ATA3431, contributed to the reduction in operating expenses.
A key strategic development was the ongoing transition of responsibilities for tab-cel to Pierre Fabre under the amended and restated Commercialization Agreement. This included the transfer of manufacturing, clinical development, and regulatory activities, with Pierre Fabre assuming the associated costs. In exchange, Atara agreed to reduce the amount of certain potential future milestone payments. The company received $60 million in milestone payments from Pierre Fabre in 2024, and is entitled to receive up to $308 million in remaining milestone payments upon achieving certain regulatory and commercial milestones in the Initial Territory, and up to $556 million in additional potential milestone payments in the Additional Territory.
Operationally, Atara completed several workforce reductions throughout 2025, resulting in restructuring charges of $12.6 million. These reductions were part of a broader strategy to prioritize key research and development programs and reduce the company's expense profile. As of December 31, 2025, Atara had 14 employees. The company's board of directors continues to evaluate potential strategic transactions to maximize value for stockholders, but there is no assurance that a transaction will be completed. The company's existing cash resources are not sufficient to fund planned operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics develops allogeneic T-cell immunotherapies targeting Epstein-Barr virus (EBV)-associated diseases, primarily focusing on its approved product Ebvallo (tab-cel) for EBV-positive post-transplant lymphoproliferative disease (PTLD). Leveraging a proprietary EBV T-cell platform, Atara creates off-the-shelf treatments designed for rapid delivery to immunocompromised patients. The company partners with Pierre Fabre for commercialization in Europe and select global markets, operating through licensing, manufacturing, and royalty-based revenue models.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.